Fendiline significantly abrogates signaling transduction downstream of the constitutively active KRAS and subsequently blocks proliferation of pancreatic, colon, lung, and endometrial cancer cell lines expressing an oncogenic mutant KRAS [66]. This evidence concerns the gene KRAS and endometrial cancer.